Abstract 20656: Publication Rates of Abstracts Presented at Major Cardiovascular Subspecialty Conferences
Introduction: Peer review and publication of all research is a vital requirement in science. Scientific meetings aim to educate and introduce new scientific advances. Although abstracts submitted to scientific meetings undergo peer review, acceptance can be affected by limitations such as limited number of characters and hence information permitted and time provided for reviewers to review many abstracts. The rate at which accepted abstracts result in published manuscripts may provide insight into their scientific merit and/or potential publication bias. The aim of this study was to assess publication rates of abstract presented at major cardiovascular conferences.
Methods and Results: We conducted a pubmed search to evaluate the publication status of 4,300 abstracts presented at 8 major meetings in 2011 using the abstract title and the names of the first and last authors of the abstract. The meeting sponsors included the American Heart Association (AHA), American College of Cardiology (ACC), Heart Failure Society of America, American Society of Echocardiography, Heart Rhythm Society, National Lipid Association, the Society for Cardiovascular Angiography and Intervention, and the Atherosclerosis, Thrombosis, and Vascular Biology. Overall, 39% (range 17.3% to 47.9%) of presented abstracts were published within 5 years of the conference (table). The publication rates for the 2 major conferences (AHA/ACC) were numerically higher compared to the subspecialty conferences at 47.9% and 35.4% respectively.
Conclusions: Only a little over one third of abstracts presented at major scientific cardiology meetings are published as manuscripts within 5 years of presentation. Understanding reasons for the limited subsequent manuscript publication rate may provide insight into potential issues regarding abstract selection and barriers to potential publication (such as publication bias) and need to be further explored.
Author Disclosures: B. Owen: None. J. Hoff: None. D. Aguilar: None. A. Denktas: None. S. Virani: Other; Modest; Member of the ACC. N. Lakkis: None. B. Bozkurt: None. A. Deswal: None. T. Shah: None. A. Misra: None. H. Jneid: None. C. Ballantyne: Consultant/Advisory Board; Modest; Abbott Diagnostics, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc, Novartis, Regeneron, Roche Diagnostic. Research Grant; Significant; NIH, AHA, ADA. Other Research Support; Significant; Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo. Consultant/Advisory Board; Significant; Astra Zeneca, Merck, Pfizer, Sanofi-Synthelabo. V. Nambi: None.
- © 2016 by American Heart Association, Inc.